Predict your next investment

HEALTHCARE | Biotechnology
humacyte.com

See what CB Insights has to offer

Founded Year

2004

Stage

Corporate Minority - P2P | IPO

Total Raised

$438.81M

About Humacyte

Humacyte (NASDAQ: HUMA) is a medical research, discovery, and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its platform to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis.

Humacyte Headquarter Location

2525 E. NC Highway 54

Durham, North Carolina, 27713,

United States

919-313-9633

Latest Humacyte News

Humacyte Announces the Appointments of Three Surgical and Cardiovascular Opinion Leaders to Advisory Roles

Dec 31, 2021

Durham, North Carolina, UNITED STATES DURHAM, N.C., Dec. 31, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Surgical Key Opinion Leaders (KOLs) Alan P. Kypson, M.D., FACS; Luigi Pascarella, M.D., FACS; and Todd E. Rasmussen, M.D., FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, the KOLs will lend their expertise and support to guide the education and clinical advancement efforts of the Human Acellular VesselTM (HAV) and help identify opportunities to advance the Company's early stage complex tissue constructs pipeline and platform. Humacyte’s HAV are engineered off-the-shelf replacement vessels currently being evaluated in advanced-stage clinical trials in vascular trauma, arteriovenous access for hemodialysis and peripheral arterial disease (PAD). The HAV are also being used to treat severe PAD patients under an investigator-sponsored IND #27864, filed with the U.S. Food and Drug Administration (FDA) by Dr. Rasmussen, at Mayo Clinic in Rochester, Minn. “Drs. Kypson, Pascarella and Rasmussen are luminaries in the fields of cardiac, vascular and trauma surgery, and we’ve had the pleasure of working with them in various capacities as we’ve developed the HAV,” said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. “We’re thrilled to now formalize their roles as foundational advisors to our clinical and surgical teams, as we prepare for our next phase of growth, anticipated commercialization of the HAV in its initial vascular indications, and planned expansion of the applications for our off-the-shelf regenerative medicine technology.” Dr. Kypson is a cardiothoracic surgeon at the University of North Carolina Rex Hospital, in Raleigh, N.C. Previously, he served as Professor of Surgery at the Brody School of Medicine and Chief of the Division of Cardiothoracic Surgery at the East Carolina Heart Institute. Dr. Kypson has led the large animal preclinical development of Humacyte’s vessels in coronary artery bypass surgery for more than a decade, and has authored more than 100 publications, primarily in the field of cardiovascular surgery. Dr. Pascarella is a vascular surgeon and an Associate Professor and Vice-Chair of Surgery at the University of North Carolina School of Medicine in Chapel Hill, N.C. Dr. Pascarella completed a Vascular Biology Research Fellowship in the Department of Bioengineering at University of California San Diego and his post-graduate surgical training at Duke University. He has performed preclinical studies on several animal models of vascular disease, including studies with the HAV. Dr. Pascarella has authored many publications in peer-reviewed medical journals, with a focus on vascular surgery, aortic disease and medical education. Dr. Rasmussen is Professor and Vice-Chair for education in the department of surgery and a senior associate consultant in the division of vascular and endovascular surgery at Mayo Clinic. Prior to joining Mayo, Dr. Rasmussen served nearly three decades in the U.S. Air Force, retiring at the rank of Colonel in 2021. During his time in the Air Force, Dr. Rasmussen completed several tours of duty in the Middle East and initiated a vascular injury and hemorrhage control research and innovation program. Dr. Rasmussen’s research has resulted in more than 300 publications, primarily in the fields of vascular injury and shock, including two textbooks, the Handbook of Patient Care in Vascular Disease and Rich’s Vascular Trauma. He is also co-inventor of the lifesaving REBOA device, a minimally invasive technique to manage severe hemorrhage and shock. About Humacyte Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit  www.Humacyte.com . Humacyte Investor Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Humacyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Humacyte is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M

Medical Devices

7,891 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Humacyte Patents

Humacyte has filed 10 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Cardiac surgery
  • Kidney diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/7/2018

7/13/2021

Inflammations, Implants (medicine), Digestive system surgery, Syndromes, Kidney diseases

Grant

Application Date

11/7/2018

Grant Date

7/13/2021

Title

Related Topics

Inflammations, Implants (medicine), Digestive system surgery, Syndromes, Kidney diseases

Status

Grant

Humacyte Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Humacyte Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.